Business
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Reviva Pharmaceuticals","displaySize":"","headline":null,"caption":"Reviva Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D8sDX1mL7wV8j6M4A9rWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8","width":300,"height":138}},"lazy":false},{"type":"text","content":"– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial –","length":152,"tagName":"p"},{"type":"text","content":"– Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 –","length":89,"tagName":"p"},{"type":"text","content":"– Full data set from RECOVER OLE expected in Q2 2025 –","length":54,"tagName":"p"},{"type":"text","content":"CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024 and summarized recent business highlights.","length":440,"tagName":"p"},{"type":"text","content":"“Our late stage brilaroxazine program has consistently shown what we believe to be robust broad-spectrum efficacy across all major symptom domains of schizophrenia and a well-tolerated safety profile. Importantly, initial long-term data from our OLE study showed that these favorable efficacy and safety findings were sustained over time. We expect to report the full data set from the RECOVER OLE study, which will also include vocal and blood biomarker data as additional independent measures of efficacy, in the second quarter of 2025,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “Brilaroxazine has a robust data package that includes a successful placebo-controlled Phase 3 trial with a long-term open label extension for up to 1-year, a successful Phase 2 study and a compelling drug-drug interaction study. We believe the differentiated po...